Pharma
BioTech
AgTech
Cannabis/CBD
CleanTech
SaaS
Fintech
Featured Investment Opportunities Vetted to Give You the EDGE.
highway 33 listing landing Thank you for visiting Investors Edge. Every week, we select thoroughly vetted investment opportunities that may be of interest to you—in specialized industries including cannabis, CBD/Hemp, pharma, and biotech. Here are featured listings chosen from our current inventory of clients.
Cannabis Dispensary Licenses Available Now in Nevada
highway 33 listing landing Don’t miss this opportunity. Nevada is already a proven lucrative cannabis market:
- 2019 sales, $645M
- Projected to grow at a 20% CAGR to $1.4B in 2024
- Second only to Colorado as the highest cannabis spend per capita at $242
Dispensary licenses are available throughout the state.
For more information, click the link following each county location:
- Pershing County – Home to 75,000+ annual Burning Man festival attendees
- Storey County – Home to Reno-Tahoe Industrial Center (Tesla, Google, Walmart, Panasonic)
- Lyon County – Access to Reno, Carson City, and Reno-Tahoe Industrial Center (Tesla, Google, Walmart, Panasonic)
- Humboldt County – I-80 corridor and shared border with Idaho
- White Pine County – Shared border with UT
- Mineral County – Primary highway connecting Las Vegas and Reno/Tahoe
- Lander County – I-80 corridor
Please contact us for details to be provided upon signing a mutual NDA and providing POF. Click here
OR, connect with us personally at Info@Highway33.com or 1 (800) 684-9238 ext. 700.
Poised to Be the World Leader in Production of Cannabinoid APIs
Pharmaceutical cannabis is the future of large-volume, stabilized, multi-national, medical-grade production. Medical-grade cannabis requires Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs) produced in a current Good-Manufacturing-Practices (cGMP) facility, to the highest global standards, as established by the European Union (EU). Our client’s mission is to produce the highest quality cannabis APIs in the world in large volumes, with precision consistency, at or below globally competitive prices. The venture is managed by a seasoned, multi-faceted team—executives with experience at McKinsey Hedge Funds, cannabis testing labs, and the pharmaceutical industries. They have already established customer relationships in the newly opening Mexico market in order to place a significant majority of production capacity in the Mexico/LatAm pharmaceutical, nutraceutical and packaged-goods supply chains. Additional-volume, API-sales channels are being developed with entrenched partners in Brazil and Argentina. Plans include subsequent sales into China, the EU and Canada, expected as soon as regulations permit.
Capital raise is U.S. $8.5M in equity financing, with uses to include: expansion of the extraction and manufacturing facility, EU cGMP certification, development of robust customer R&D support infrastructure, continuation of the development and expansion of cultivation operations, and for general working capital.
Please contact us for details to be provided upon signing a mutual NDA and providing POF. Click here
OR, connect with us personally at Info@Highway33.com or 1 (800) 684-9238 ext. 700.
A Primary Source of Hemp-based Cannabinoid APIs and a Unique Opportunity
In an industry estimated to grow to over $16 billion by 2024, our client is one of the largest privately-owned, primary-source manufacturers of hemp-based cannabinoid-active ingredients. Consumer adoption of products containing CBD for human and pet consumption has exploded over the last two years, and the industry is dependent on these cannabinoid-active ingredients as the basis for all products containing CBD and other cannabinoids.
Our client, with revenue of $50M in 2019 —a $16M EDITDA—is on track to $60M in 2020. Why? A $20M contract with one of the world’s largest CPG companies. The opportunity for you to consider: This client has only $3M of the $8M remaining to fill for their last financing round before a large SPAC acquires them this year, creating a highly rewarding liquidity event for investors.
Please contact us for details to be provided upon signing a mutual NDA and providing POF. Click here
OR, connect with us personally at Info@Highway33.com or 1 (800) 684-9238 ext. 700.
Technology Selected to the Inaugural Class of the World’s Largest Climate-Tech Innovation Cohort
Our client has engineered a preemptive technology to bring the power of renewable sunlight indoors through fiber optic cables. So innovative and game-changing, they were selected to join the Cohort 417 program of Third Derivative (D3), a global, vertically integrated engine for climate innovation. Of 620 startups from 61 countries who applied for potential venture funding and support, our client was among the 50 companies chosen—for creating a technology proven to increase controlled-environment crop yield while lowering energy usage and production costs.
The company’s patented collection of fiber-optic technologies delivers up to 10x the energy of PV solar panels driving LEDs, a breakthrough that has received millions in funding from the US Department of Energy and angel investors. The company’s Sunlight-as-a-Service business model, with the SunPath Sunshine Inside Platform™, surpasses the limits of the LED lighting and price-performance.
Through us, the client is closing their seed round for $1.5 million at a pre-money of $9 million for production ramp up and is beginning a Series A round in Q1 2021 for $5 million to fully commercialize the technology.
Please contact us for details to be provided upon signing a mutual NDA and providing POF. Click here
OR, connect with us personally at Info@Highway33.com or 1 (800) 684-9238 ext. 700.
Safe Harbor Statement
The descriptions of these investment opportunities are for informational purposes only and do not represent an offering of the sale of securities in any of the companies listed. Offers to purchase securities in a financing transaction, if and when made, will be made solely to a limited number of accredited investors in a private placement exempt from the registration requirements under the Securities Act of 1933, as amended.